Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MITF | O75030 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28836149 | 0.98 | KMT2A (0.43) | METAP2METAP1ENPP3ENPP1KMT2A | |
| SCHEMBL17066733 | 0.98 | ENPP3 (0.46) | METAP2METAP1ENPP3ENPP1KMT2A | |
| SCHEMBL17983446 | 0.91 | ENPP3 (0.36) | METAP2METAP1ENPP3ENPP1KMT2A | |
| SCHEMBL28574508 | 0.83 | MAPT (0.47) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3669956 | 0.83 | MEN1 (0.43) | KMT2AMEN1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL24484639 | 0.83 | RAB9A (0.47) | METAP2KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL15823275 | 0.83 | RAD51 (0.43) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL13545715 | 0.83 | PDGFRB (0.44) | METAP2KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL8010306 | 0.83 | KEAP1 (0.41) | METAP2KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL1008901 | 0.83 | MEN1 (0.46) | KMT2AMEN1KDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8173699-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | ANDERSKEWITZ RALF | 2010-07-29 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| WO-2006114371-A1 | NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | METAP2 3781/4885METAP1 3458/4885ENPP3 1030/4885 |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | MALT1, IL1B, RORC | METAP2 3696/4885METAP1 2080/4885ENPP3 2588/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | METAP2 3781/4885METAP1 3458/4885ENPP3 1030/4885 |
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | METAP2 4459/4885METAP1 4102/4885ENPP3 1104/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | METAP2 3781/4885METAP1 3458/4885ENPP3 1030/4885 |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | METAP2 1943/4885METAP1 971/4885ENPP3 2540/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | METAP2 1656/4885METAP1 1123/4885ENPP3 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.